Cevidoplenib

Overview

Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase ( Syk ) , with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC 50 s of 6.2 nM ( Syk ), 1.859 μM ( Jak2 ), 5.807 μM ( Jak3 ), 0.412 μM ( RET ), 0.687 μM (KOR), 1.783 μM ( FLT3 ), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM ( Pyk2 ), respectively.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Rheumatoid Arthritis | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Syk

Product Information

• Catalog No.: HY-109082
• CAS No.: 1703788-21-9
• Molecular Formula: C25H27N7O3
• Molecular Weight: 473.53
• Purity: 99.58%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (5.28 mM); Clear solution
• Availability: In-stock

Source

Original product source